Zydus Cadila gets EIR from USFDA for Pharma SEZ plant at Ahmedabad
NEW DELHI: Drug firm Zydus Cadila said it has received establishment inspection report from the US health regulator for its manufacturing facility at Pharma SEZ at Ahmedabad.
The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement.
The company's "formulations manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit", it added.
Shares of Cadila Healthcare, the listed entity of Zydus Group were trading at Rs 499.75 per scrip in the afternoon trade on BSE, down 0.26 per cent from the previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd